
HAEMONETICS CORP/MASS
HAENYSETrading Snapshot
- Day Range
- $127.45 β $130.12
- 52-Week Range
- $47.32 β $88.59
- Volume
- $1.69B
- Avg Volume
- $1.55B
- Shares Outstanding
- 45.5M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.33B
- Last Q Revenue
- $339M
- P/E Ratio
- 40.9
- P/S Ratio
- 2.9x
- EPS (TTM)
- $2.05
- Dividend Yield
- β
Why Investors Own HAE
- βHigh-growth profile β revenue up +14.2% YoY with expanding US Equity exposure.
- βHealthy economics β 64% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HAEMONETICS CORP/MASS
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
HAEMONETICS CORP/MASS tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift HAE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
HAEMONETICS CORP/MASS announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.